CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?

被引：20

作者：

Calabro, Luana ^{[1
]}

Ceresoli, Giovanni Luca ^{[2
]}

di Pietro, Alessandra ^{[3
]}

Cutaia, Ornella ^{[1
]}

Morra, Aldo ^{[4
]}

Ibrahim, Ramy ^{[5
]}

Maio, Michele ^{[1
]}

机构：

[1] Azienda Osped Univ Senese, Dipartimento Oncol Med, Ist Toscano Tumori, I-53100 Siena, Italy

[2] Clin Humanitas Gavazzeni, Thorac & GU Oncol Unit, Bergamo, Italy

[3] Clin Dev Oncol MedImmune, Gaithersburg, MD USA

[4] Euganea Med Diagnost Ctr, Dept Radiol, Padua, Italy

[5] AstraZeneca, Global Med Dev, Clin, Immunooncol, Gaithersburg, MD USA

来源：

CANCER IMMUNOLOGY IMMUNOTHERAPY | 2015年 / 64卷 / 01期

关键词：

Mesothelioma; Anti-CTLA4; mAb; Tremelimumab; Immunotherapy; NIBIT-2013; MALIGNANT-PLEURAL-MESOTHELIOMA; CELL LUNG-CANCER; PHASE-III; DOUBLE-BLIND; RECIST CRITERIA; PEMETREXED PLUS; SUPPORTIVE CARE; OPEN-LABEL; CHEMOTHERAPY; MULTICENTER;

D O I：

10.1007/s00262-014-1609-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

No second-line treatment significantly prolongs the survival of malignant mesothelioma patients who have a high unmet medical need. Here, we comment on the therapeutic potential of cytotoxic T-lymphocyte-associated protein (CTLA)4-blockade by the anti-CTLA4 monoclonal antibody (mAb) tremelimumab of refractory malignant mesothelioma patients. We also focus on the critical role of an accurate tumor assessment in the course of treatment with immunomodulating mAb. Finally, treatment with potentially effective, second-generation checkpoint(s) inhibiting mAb, as well future combination strategies in this deadly disease, will be discussed.

引用

页码：105 / 112

页数：8

共 43 条

[1]

Variability in mesothelioma tumor response classification [J].

Armato, SG ;

Ogarek, JL ;

Starkey, A ;

Vogelzang, NJ ;

Kindler, HL ;

Kocherginsky, M ;

MacMahon, H .

AMERICAN JOURNAL OF ROENTGENOLOGY, 2006, 186 (04) :1000-1006

[2]

Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma [J].

Bograd, Adam J. ;

Suzuki, Kei ;

Vertes, Eva ;

Colovos, Christos ;

Morales, Eduardo A. ;

Sadelain, Michel ;

Adusumilli, Prasad S. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (11) :1509-1527

[3]

Imaging of mediastinal lymph nodes: CT, MR, and FDG PET [J].

Boiselle, PM ;

Patz, EF ;

Vining, DJ ;

Weissleder, R ;

Shepard, JO ;

McLoud, TC .

RADIOGRAPHICS, 1998, 18 (05) :1061-1069

[4]

Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study [J].

Buikhuisen, Wieneke A. ;

Burgers, Jacobus A. ;

Vincent, Andrew D. ;

Korse, Catharina M. ;

van Klaveren, Rob J. ;

Schramel, Franz M. N. H. ;

Pavlakis, Nick ;

Nowak, Anna K. ;

Custers, Frank L. J. ;

Schouwink, J. Hugo ;

Gans, Steven J. M. ;

Groen, Harry J. M. ;

Strankinga, Wim F. M. ;

Baas, Paul .

LANCET ONCOLOGY, 2013, 14 (06) :543-551

[5]

BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma [J].

Busacca, Sara ;

Sheaff, Michael ;

Arthur, Kenneth ;

Gray, Steven G. ;

O'Byrne, Kenneth J. ;

Richard, Derek J. ;

Soltermann, Alex ;

Opitz, Isabelle ;

Pass, Harvey ;

Harkin, D. Paul ;

Quinn, Jennifer E. ;

Fennell, Dean A. .

JOURNAL OF PATHOLOGY, 2012, 227 (02) :200-208

[6]

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma [J].

Byrne, MJ ;

Nowak, AK .

ANNALS OF ONCOLOGY, 2004, 15 (02) :257-260

[7]

A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients. [J].

Calabro, Luana ;

Morra, Aldo ;

Fonsatti, Ester ;

Cutaia, Ornella ;

Fazio, Carolina ;

Danielli, Riccardo ;

Giannarelli, Diana ;

Altomonte, Maresa ;

Di Giacomo, Anna Maria ;

Maio, Michele .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[8]

Immune checkpoint blockade in malignant mesothelioma A novel therapeutic strategy against a deadly disease? [J].

Calabro, Luana ;

Maio, Michele .

ONCOIMMUNOLOGY, 2014, 3 (01)

[9]

Biomarkers for immune checkpoint inhibitors Reply [J].

Calabro, Luana ;

Maio, Michele .

LANCET ONCOLOGY, 2014, 15 (01) :E1-E2

[10]

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial [J].

Calabro, Luana ;

Morra, Aldo ;

Fonsatti, Ester ;

Cutaia, Ornella ;

Amato, Giovanni ;

Giannarelli, Diana ;

Di Giacomo, Anna Maria ;

Danielli, Riccardo ;

Altomonte, Maresa ;

Mutti, Luciano ;

Maio, Michele .

LANCET ONCOLOGY, 2013, 14 (11) :1104-1111

← 1 2 3 4 5 →